| Year |
Citation |
Score |
| 2024 |
Ortigoza MB, Mobini CL, Rocha HL, Bartlett S, Loomis CA, Weiser JN. Inhibiting influenza virus transmission using a broadly acting neuraminidase that targets host sialic acids in the upper respiratory tract. Mbio. e0220323. PMID 38206008 DOI: 10.1128/mbio.02203-23 |
0.681 |
|
| 2023 |
Ortigoza MB, Mobini CL, Rocha HL, Bartlett S, Loomis CA, Weiser JN. Targeting host sialic acids in the upper respiratory tract with a broadly-acting neuraminidase to inhibit influenza virus transmission. Biorxiv : the Preprint Server For Biology. PMID 37398388 DOI: 10.1101/2023.06.02.543524 |
0.54 |
|
| 2023 |
Rodriguez-Rodriguez BA, Ciabattoni GO, Duerr R, Valero-Jimenez AM, Yeung ST, Crosse KM, Schinlever AR, Bernard-Raichon L, Rodriguez Galvan J, McGrath ME, Vashee S, Xue Y, Loomis CA, Khanna KM, Cadwell K, ... ... Ortigoza MB, et al. A neonatal mouse model characterizes transmissibility of SARS-CoV-2 variants and reveals a role for ORF8. Nature Communications. 14: 3026. PMID 37230979 DOI: 10.1038/s41467-023-38783-0 |
0.308 |
|
| 2022 |
Rodriguez-Rodriguez BA, Ciabattoni G, Valero-Jimenez AM, Crosse KM, Schinlever A, Galvan JR, Duerr R, McGrath M, Desvignes L, Frieman M, Ortigoza MB, Dittmann M. A neonatal mouse model characterizes transmissibility of SARS-CoV-2 variants and reveals a role for ORF8. Biorxiv : the Preprint Server For Biology. PMID 36238716 DOI: 10.1101/2022.10.04.510658 |
0.343 |
|
| 2022 |
Duerr R, Dimartino D, Marier C, Zappile P, Wang G, Plitnick J, Griesemer SB, Lasek-Nesselquist E, Dittmann M, Ortigoza MB, Prasad PJ, St George K, Heguy A. Delta-Omicron recombinant SARS-CoV-2 in a transplant patient treated with Sotrovimab. Biorxiv : the Preprint Server For Biology. PMID 35411351 DOI: 10.1101/2022.04.06.487325 |
0.305 |
|
| 2021 |
Zangari T, Ortigoza MB, Lokken-Toyli KL, Weiser JN. Type I Interferon Signaling Is a Common Factor Driving Streptococcus pneumoniae and Influenza A Virus Shedding and Transmission. Mbio. 12. PMID 33593970 DOI: 10.1128/mBio.03589-20 |
0.499 |
|
| 2018 |
Ortigoza MB, Blaser SB, Zafar MA, Hammond AJ, Weiser JN. An Infant Mouse Model of Influenza Virus Transmission Demonstrates the Role of Virus-Specific Shedding, Humoral Immunity, and Sialidase Expression by Colonizing Streptococcus pneumoniae. Mbio. 9. PMID 30563897 DOI: 10.1128/Mbio.02359-18 |
0.579 |
|
| 2012 |
Martínez-Gil L, Ayllon J, Ortigoza MB, García-Sastre A, Shaw ML, Palese P. Identification of small molecules with type I interferon inducing properties by high-throughput screening. Plos One. 7: e49049. PMID 23145065 DOI: 10.1371/Journal.Pone.0049049 |
0.638 |
|
| 2012 |
Ortigoza MB, Dibben O, Maamary J, Martinez-Gil L, Leyva-Grado VH, Abreu P, Ayllon J, Palese P, Shaw ML. A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferon. Plos Pathogens. 8: e1002668. PMID 22577360 DOI: 10.1371/Journal.Ppat.1002668 |
0.461 |
|
| 2010 |
König R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, Bhattacharyya S, Alamares JG, Tscherne DM, Ortigoza MB, Liang Y, Gao Q, Andrews SE, Bandyopadhyay S, De Jesus P, Tu BP, et al. Human host factors required for influenza virus replication. Nature. 463: 813-7. PMID 20027183 DOI: 10.1038/Nature08699 |
0.727 |
|
| 2006 |
Zamarin D, Ortigoza MB, Palese P. Influenza A virus PB1-F2 protein contributes to viral pathogenesis in mice. Journal of Virology. 80: 7976-83. PMID 16873254 DOI: 10.1128/Jvi.00415-06 |
0.644 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2023 |
Duerr R, Dimartino D, Marier C, Zappile P, Wang G, François F, Ortigoza MB, Iturrate E, Samanovic MI, Mulligan MJ, Heguy A. Selective adaptation of SARS-CoV-2 Omicron under booster vaccine pressure: a multicentre observational study. Ebiomedicine. 97: 104843. PMID 37866115 DOI: 10.1016/j.ebiom.2023.104843 |
0.281 |
|
| 2021 |
Hammond AJ, Binsker U, Aggarwal SD, Ortigoza MB, Loomis C, Weiser JN. Neuraminidase B controls neuraminidase A-dependent mucus production and evasion. Plos Pathogens. 17: e1009158. PMID 33819312 DOI: 10.1371/journal.ppat.1009158 |
0.24 |
|
| 2023 |
Duerr R, Zhou H, Tada T, Dimartino D, Marier C, Zappile P, Wang G, Plitnick J, Griesemer SB, Girardin R, Machowski J, Bialosuknia S, Lasek-Nesselquist E, Hong SL, Baele G, ... ... Ortigoza MB, et al. Delta-Omicron recombinant escapes therapeutic antibody neutralization. Iscience. 26: 106075. PMID 36844451 DOI: 10.1016/j.isci.2023.106075 |
0.234 |
|
| 2022 |
Gray-Gaillard SL, Solis S, Monteiro C, Chen HM, Ciabattoni G, Samanovic MI, Cornelius AR, Williams T, Geesey E, Rodriguez M, Ortigoza MB, Ivanova EN, Koralov SB, Mulligan MJ, Herati RS. Molecularly distinct memory CD4+ T cells are induced by SARS-CoV-2 infection and mRNA vaccination. Biorxiv : the Preprint Server For Biology. PMID 36415470 DOI: 10.1101/2022.11.15.516351 |
0.19 |
|
| 2009 |
Sachdev DD, Zerhouni-Layachi B, Ortigoza M, Profy AT, Tuen M, Hioe CE, Klotman ME. The differential binding and activity of PRO 2000 against diverse HIV-1 envelopes. Journal of Acquired Immune Deficiency Syndromes (1999). 51: 125-9. PMID 19349871 DOI: 10.1097/Qai.0B013E31819F9E31 |
0.121 |
|
| 2023 |
Yoon H, Li Y, Goldfeld KS, Cobb GF, Sturm-Reganato CL, Ostrosky-Zeichner L, Jayaweera DT, Philley JV, Desruisseaux MS, Keller MJ, Hochman JS, Pirofski LA, Ortigoza MB. COVID-19 Convalescent Plasma Therapy: Long-term Implications. Open Forum Infectious Diseases. 11: ofad686. PMID 38269049 DOI: 10.1093/ofid/ofad686 |
0.103 |
|
| 2022 |
Park H, Tarpey T, Liu M, Goldfeld K, Wu Y, Wu D, Li Y, Zhang J, Ganguly D, Ray Y, Paul SR, Bhattacharya P, Belov A, Huang Y, Villa C, ... ... Ortigoza MB, et al. Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma. Jama Network Open. 5: e2147375. PMID 35076698 DOI: 10.1001/jamanetworkopen.2021.47375 |
0.044 |
|
| 2022 |
Troxel AB, Petkova E, Goldfeld K, Liu M, Tarpey T, Wu Y, Wu D, Agarwal A, Avendaño-Solá C, Bainbridge E, Bar KJ, Devos T, Duarte RF, Gharbharan A, Hsue PY, ... ... Ortigoza MB, et al. Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis. Jama Network Open. 5: e2147331. PMID 35076699 DOI: 10.1001/jamanetworkopen.2021.47331 |
0.029 |
|
| 2021 |
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O'Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, et al. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial. Jama Internal Medicine. PMID 34901997 DOI: 10.1001/jamainternmed.2021.6850 |
0.01 |
|
| Hide low-probability matches. |